Throughout history, both men and women have perpetrated this act, but study of maternal filicide is more extensive. See also
Postpartum blues
Antenatal depression
Gender disappointment
Psychiatric disorders of childbirth
Sex after pregnancy
Breastfeeding and mental health

References
External links

Postpartum depression at Curlie
"Depression during and after pregnancy fact sheet". Womenshealth.gov. 6 March 2009. Archived from the original on 1 March 2012. Postnatal Depression, information from the mental health charity The Royal College of Psychiatrists
NHS Choices Health A-Z: Postnatal depression
Postpartum Depression and the Baby Blues - HelpGuide.org
It is a controlled substance in the United States and is considered to have a low misuse potential. Pharmacology
Pharmacodynamics
Lemborexant is a dual antagonist of the orexin OX1 and OX2 receptors. It associates and dissociates from the orexin receptors more rapidly than certain other orexin receptor antagonists, such as suvorexant, and this may cause it to have a shorter duration of action. Pharmacokinetics
The bioavailability of lemborexant is good and is at least 87%. The time to peak levels of lemborexant is 1 to 3 hours. A high-fat and high-calorie meal has been found to delay the time to peak levels by 2 hours. Its plasma protein binding in vitro is 94%. Lemborexant is metabolized primarily by CYP3A4 and to a lesser extent by CYP3A5. The "effective" half-life of lemborexant is 17 to 19 hours while its terminal elimination half-life is 55 hours. The medication is excreted in feces (57%) and to a lesser extent urine (29%). Although lemborexant has a longer terminal elimination half-life than suvorexant, it appears to be more rapidly cleared than suvorexant in the earlier phases of elimination. In addition, lemborexant dissociates from the orexin receptors more rapidly than does suvorexant. These differences may allow for comparatively reduced next-day effects such as daytime somnolence with lemborexant. History
In June 2016, Eisai initiated Phase III clinical trials in the United States, France, Germany, Italy, Japan, Poland, Spain and the UK.In December 2019, lemborexant was approved for use in the United States based on results from the SUNRISE 1 and SUNRISE 2 Phase III clinical trials.